Story

Braveheart Bio Raises $439.9 Million in Upsized Nasdaq IPO

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
Braveheart Bio Raises $439.9 Million in Upsized Nasdaq IPO
Text size
Background

Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company, announced the closing of its upsized initial public offering, raising gross proceeds of $439.9 million. The successful debut provides the company with significant capital as it develops its lead drug candidate for a serious heart condition.

Offering Details

According to a company press release, Braveheart Bio sold a total of 24,437,500 shares of common stock at a price of $18.00 per share. The final share count was larger than initially planned due to the full exercise by underwriters of their option to purchase an additional 3,187,500 shares, a signal of strong investor demand.

The gross proceeds of $439.9 million are calculated before the deduction of underwriting discounts, commissions, and other offering-related expenses. All shares in the offering were sold by Braveheart Bio.

Market Debut and Pipeline

Sample IUX Markets – In-articleAd

The company's shares began trading on the Nasdaq Global Market on August 6, 2026, under the ticker symbol BRVE. The capital raised is expected to fund the development of its pipeline, led by its primary product candidate, BHB-1893.

BHB-1893 is an oral, small-molecule cardiac myosin inhibitor being developed to treat hypertrophic cardiomyopathy, a disease that causes the heart muscle to thicken. The drug is being studied for both obstructive and non-obstructive forms of the condition.

Underwriters and Regulatory Process

A consortium of investment banks managed the offering, with Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor serving as joint book-running managers. The registration statements for the offering were filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on August 5, 2026, clearing the final regulatory hurdle for the IPO.

Read next

More on Stocks
Back to latest news

LATEST